BC
CBIO

Broadfin Capital’s Crescent Biopharma CBIO Stock Holding History

Broadfin Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,218
Closed -$2.48M – 49
2017
Q2 		$2.48M Buy
+2,218
New +$1.83M 0.3% 45

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Broadfin Capital's CBIO Position: Q3 2017 in Review

Broadfin Capital sold out of Crescent Biopharma (CBIO) in Q3 2017, closing a stake of 2,218 shares — an estimated $2.48M sold.

Broadfin Capital first reported a position in CBIO in Q2 2017 and held it in 1 quarter. The position peaked at $2.48M in Q2 2017. 58 funds tracked by Wall St. Rank hold CBIO as of Q3 2017.

  • Broadfin Capital reported no remaining Crescent Biopharma position as of Q3 2017 after selling out during the quarter.
  • Broadfin Capital sold 2,218 Crescent Biopharma shares in Q3 2017, an estimated $2.48M.
  • Broadfin Capital first reported a position in Crescent Biopharma in Q2 2017 and held it in 1 quarter.
  • Broadfin Capital's Crescent Biopharma position peaked at $2.48M in Q2 2017.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2017.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.